Drug Profile

ZZ 6398

Alternative Names: SIPI-6398; ZZ-6398

Latest Information Update: 10 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zhongze Therapeutics
Class Antipsychotics
Mechanism of Action 5-HT1A serotonin receptor antagonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Serotonin 5-HT2A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Jun 2026 Phase-I development is ongoing in China (Zhongze Therapeutics pipeline, June 2026)
04 Jun 2026 Shanghai Zhongze Therapeutics plans a phase I/II trial for Schizophrenia (PO, Tablet) in August 2026 (NCT07626034)
28 Oct 2024 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com